Poster - Wed Eve-46: Quantitative Evaluation on the Accuracy of Image Registration Methods in SPECT Guided Radiation Therapy for Lung Cancer Patients

2009 ◽  
Vol 36 (9Part2) ◽  
pp. 4312-4312
Author(s):  
L Yin ◽  
L Tang ◽  
G Hamarneh ◽  
V Moiseenko ◽  
A Celler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Image Registration ◽  
Cancer Patients ◽  
Quantitative Evaluation ◽  
Lung Cancer Patients

scholarly journals Effect of deformable registration on the dose calculated in radiation therapy planning CT scans of lung cancer patients a)

2014 ◽  
Vol 42 (1) ◽  
pp. 391-399 ◽  
Author(s):  
Alexandra R. Cunliffe ◽  
Clay Contee ◽  
Samuel G. Armato ◽  
Bradley White ◽  
Julia Justusson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Deformable Registration ◽  
Ct Scans ◽  
Therapy Planning ◽  
Lung Cancer Patients ◽  
Radiation Therapy Planning ◽  
Planning Ct

Plasmatic Cytokine Levels in Lung Cancer Patients Undergoing Definitive Radiation Therapy

2013 ◽  
Vol 87 (2) ◽  
pp. S513
Author(s):  
M. Trovo ◽  
T.M. Bortolin ◽  
C. Furlan ◽  
R. Tedeschi ◽  
J. Polesel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Cytokine Levels

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases

2003 ◽  
Vol 21 (13) ◽  
pp. 2529-2536 ◽  
Author(s):  
Minesh P. Mehta ◽  
Patrick Rodrigus ◽  
C.H.J. Terhaard ◽  
Aroor Rao ◽  
John Suh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Treatment Benefit ◽  
Motexafin Gadolinium ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Brain Radiation

Purpose: This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd). Patients and Methods: Patients were randomly assigned to 30 Gy of WBRT ± 5 mg/kg/d MGd. Survival and time to neurologic progression determined by a blinded events review committee (ERC) were coprimary end points. Standardized investigator neurologic assessment and neurocognitive testing were evaluated. Results: Four hundred one (251 non–small-cell lung cancer) patients were enrolled. There was no significant difference by treatment arm in survival (median, 5.2 months for MGd v 4.9 months for WBRT; P = .48) or time to neurologic progression (median, 9.5 months for MGd v 8.3 months for WBRT; P = .95). Treatment with MGd improved time to neurologic progression in patients with lung cancer (median, not reached for MGd v 7.4 months for WBRT; P = .048, unadjusted). By investigator, MGd improved time to neurologic progression in all patients (median, 4.3 months for MGd v 3.8 months for WBRT; P = .018) and in lung cancer patients (median, 5.5 months for MGd v 3.7 months for WBRT; P = .025). MGd improved neurocognitive function in lung cancer patients. Conclusion: The overall results did not demonstrate significant differences by treatment arm for survival and ERC time to neurologic progression. Investigator neurologic assessments demonstrated an MGd treatment benefit in all patients. In lung cancer patients, ERC- and investigator-determined time to neurologic progression demonstrated an MGd treatment benefit. MGd may improve time to neurologic and neurocognitive progression in lung cancer.

scholarly journals The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients

2017 ◽  
Vol 12 (10) ◽  
pp. 1467-1477 ◽  
Author(s):  
Gokoulakrichenane Loganadane ◽  
Lizza Hendriks ◽  
Cécile Le Péchoux ◽  
Antonin Levy
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Current Role ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Brain Radiation
Sign in / Sign up

Export Citation Format

Share Document